1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Cardiomyopathy-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016


DelveInsight’s Report, “Cardiomyopathy-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Cardiomyopathy Report is to understand the market and pipeline status of the drugs around the Cardiomyopathy to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Cardiomyopathy. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Cardiomyopathy.
- A review of the marketed products under prescription for Cardiomyopathy, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Cardiomyopathy with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Cardiomyopathy drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Cardiomyopathy drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Cardiomyopathy drugs.
- Coverage of Cardiomyopathy Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Cardiomyopathy key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Cardiomyopathy.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Cardiomyopathy.
- API intelligence over marketed drugs forCardiomyopathyand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Cardiomyopathy.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Cardiomyopathy-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016

Illustrative Table of contents
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Cardiomyopathy
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Cardiomyopathy
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Cardiomyopathy
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer

List of Tables

- Cardiomyopathy Therapeutic Market, US, Marketed Drugs by Application Type, 2016
- Cardiomyopathy Therapeutic Market, US, Marketed Drugs by Marketing Status, 2016
- Cardiomyopathy Therapeutic Market, US, (Year), 2016
- Cardiomyopathy Marketed Drugs, API Manufacturers by US DMF Status, 2016
- Cardiomyopathy Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Cardiomyopathy Drugs, API Manufacturers, Europe by Country, 2016
- Cardiomyopathy Drugs, API Manufacturers, India by State, 2016
- Cardiomyopathy Drugs, API Manufacturers, China by Province, 2016
- Cardiomyopathy Drugs, API Manufacturers by Geography 2016
- Cardiomyopathy Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Cardiomyopathy Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2016
- Phase III Drugs for Cardiomyopathy, 2016
- Discontinued Drugs for Cardiomyopathy, 2016

List of Figures

- Cardiomyopathy Therapeutic Market, US, Marketed Drugs by Application Type (%), 2016
- Cardiomyopathy Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2016
- Cardiomyopathy Therapeutic Market, US, (Year), 2016
- Cardiomyopathy Marketed Drugs, API Manufacturers by US DMF Status (%), 2016
- Cardiomyopathy Marketed Drugs, US DMF Status Drug Specific (Number), 2016
- Cardiomyopathy Drugs, API Manufacturers, Europe by Country, 2016
- Cardiomyopathy Drugs, API Manufacturers, India by State, 2016
- Cardiomyopathy Drugs, API Manufacturers, China by Province, 2016
- Cardiomyopathy Drugs, API Manufacturers by Geography 2016
- Cardiomyopathy Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2016
- Cardiomyopathy Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Cardiovascular Surgical Devices: Technologies and Global Markets

Cardiovascular Surgical Devices: Technologies and Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Learn about the trends and developments affecting each type of cardiovascular surgical technology - Analyze trends and opportunities in major regions: North America, Europe, Asia ...

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Refurbished Medical Equipment Market: By Type (Medical Imaging, Operating Room & Surgical, Patient Monitors, Cardiovascular & Cardiology, Defibrillators, Neurology, Others) & By Region-Forecast (2016-2021)

Refurbished Medical Equipment Market: By Type (Medical Imaging, Operating Room & Surgical, Patient Monitors, Cardiovascular & Cardiology, Defibrillators, Neurology, Others) & By Region-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Refurbished medical equipment market is being primarily driven by factors like development of e-commerce platform enhancing the ease of purchase of refurbished medical equipment, growing demand for refurbished ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.